Bloomberg Kimmel Institute for Cancer Immunotherapy » Johns Hopkins Drug Discovery
1793
page,page-id-1793,page-child,parent-pageid-23,page-template,page-template-full_width,page-template-full_width-php,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

Bloomberg Kimmel Institute for Cancer Immunotherapy

Bloomberg~Kimmel Institute for Cancer Immunotherapy

The Bloomberg~Kimmel Institute for Cancer Immunotherapy led by Dr. Drew Padroll is at the forefront of discovering and developing new immune-based cancer treatments. The institute builds on pioneering discoveries, many here at Johns Hopkins, that are making it possible to trigger the immune system’s innate cancer-fighting abilities. The JHDD plays an integral part of the Bloomberg~Kimmel Institute for Cancer Immunotherapy by serving as the Drug Development Technology Center, which provides a broad range of expertise in drug discovery research to translate findings from basic and clinical research into novel cancer immunotherapy.

 

Visit Site

lowgo_bottom